Compare OSPN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | IVVD |
|---|---|---|
| Founded | 1991 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.0M | 437.1M |
| IPO Year | 2000 | 2021 |
| Metric | OSPN | IVVD |
|---|---|---|
| Price | $10.93 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.67 | $8.75 |
| AVG Volume (30 Days) | 532.8K | ★ 3.6M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.75% | N/A |
| EPS Growth | 28.77 | ★ 79.02 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $243,180,000.00 | $53,426,000.00 |
| Revenue This Year | $3.22 | $147.67 |
| Revenue Next Year | $3.16 | $22.76 |
| P/E Ratio | $5.82 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $10.07 | $0.46 |
| 52 Week High | $18.13 | $3.07 |
| Indicator | OSPN | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 53.06 |
| Support Level | $10.20 | $1.41 |
| Resistance Level | $10.98 | $1.77 |
| Average True Range (ATR) | 0.38 | 0.15 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 64.02 | 71.43 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.